Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Pfizer Burns More Money on the Inhaled Insulin Bonfire
- After burning $2.8 billion, Pfizer is throwing yet more money on the inhaled insulin bonfire. The company's announcement that it has a deal to switch former Exubera patients to MannKind's TechnoSphere is a real head-scratcher. One unanswered question is, exactly how many Exubera patients are there? Pfizer...
- Blog posts 2008-09-18
- MannKind Has Mountain to Climb If FDA Approves Afresa and TechnoSphere
- MannKind is poised for a big leap -- if the FDA allows the company to sell its drug (delivered via its TechnoSphere inhaler, pictured) it can finally start earnng some revenues. Take a look at how high that leap will have to be. So far, MannKind's net loss to shareholders...
- Blog posts 2009-07-09
- MannKind's Trendy New Insulin Inhalers: "The Dreamboat" and the "Screaming Cricket"
- MannKind's big gamble on inhalable insulin -- it's stepping into the breach exited by Pfizer's Exubera disaster with an equivalent product, Afresa -- has many skeptical. Those skeptics may want to take a look at the company's new line of trendy inhalers, still under development. by Jim Edwards
- Blog posts 2009-08-04
- Will FDA Approve MannKind's Insulin Inhaler?
- MannKind stunned the diabetic community on Tuesday after reporting in a regulatory filing that it did not foresee entering into a co-marketing agreement for its lead product candidate, the inhaled insulin product AFRESA, before the end of 2009. Prudent business decision by management -- or a sign of Big Pharma's...
- Blog posts 2009-10-09
- The Scoop on MannKind's Afresa Partnership Delay
- MannKind’s president and chief operating officer, Hakan Edstrom, explains why the company's partnership for inhaled insulin product Afresa has been delayed. by Trista Morrison
- Blog posts 2009-10-11
- MannKind's CFO Pfeffer Upbeat on Afresa's Future
- MannKind Corp.‘s announcement last month that no partnership deal was in the offing for its inhaled-insulin product Afresa this year has lead to widespread commentary about the actual clinical and commercial viability of this investigational prandial drug therapy for diabetes care. In a phone call with me on Wednesday, chief...
- Blog posts 2009-11-10
Additional Resources
- MannKind Down to Its Last $28 Million; No Revenue in Sight
- MannKind Corp., which burns cash at a rate of $83 million and $75 million per quarter, has only $46.5 billion in current assets left. So it will have to borrow $350 million from Al Mann, the company chairman, to see itself through, according to Zack's. If you check out its...
- Blog posts 2009-02-20
- NYT's MannKind Story Needlessly Quoted a Competitor Bashing Afresa
- Management at MannKind will doubtless be furious at a New York Times story over the weekend in which a vp for a rival company, Generex, was quoted casting doubt on MannKind's product. The story, under the rubric "novelties," summarized the case for MannKind's inhaled insulin product, Afresa. It quoted an...
- Blog posts 2009-10-12
- Leerink Swann & Company Initiates Coverage of MannKind Corporation (NASDAQ: MNKD)
- Yesterday after the close, Senior Biotechnology Analyst, William Tanner, Ph.D., initiated coverage of MannKind Corporation (NASDAQ: MNKD) with an Outperform rating. His investment rating is based on his belief that MannKind's Technosphere, a potential best-in-class inhaled insulin product, positions it well for partnering opportunities.
- Research articles 2005-10-13
- Research and Markets: The MannKind Corp Product Pipeline Report Delivers the Latest and the Most Comprehensive Intelligence Available on MannKind Corps Current Pipeline Portfolio
- DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c78527) has announced the addition of MannKind Corp - Product Pipeline Report to their offering.
- Research articles 2008-01-04
- Mannkind entering fray over inhaled insulin market
- MannKind Corp. marched into the American Diabetes Association's 65th annual Scientific Sessions last week looking a little bit like an underdog. But despite the fact that rival pharmaceutical companies are likely to beat MannKind to the market with competing insulin delivery products, the Valencia-based company has plenty of reasons...
- Research articles 2005-06-20
- Zacks Bull and Bear of the Day Highlights: InterDigital Communications, MannKind, Natural Resource Partners and NovaMed
- CHICAGO -- Zacks Equity Research highlights InterDigital Communications (Nasdaq:IDCC) as the Bull of the Day and MannKind Corporation (Nasdaq:MNKD) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Natural Resource Partners (NYSE:NRP) and NovaMed, Inc. (Nasdaq:NOVA). Full analysis of all four stocks is available at...
- Research articles 2006-11-06
- Schaeffer's Daily Market Blog Features MannKind, AVI BioPharma, Advanced Micro Devices, Corning, and Apollo Group
- CINCINNATI -- Among the stocks featured in the January 20 edition of Schaeffer's Market Blog are MannKind (NASDAQ:MNKD), AVI BioPharma (NASDAQ:AVII), Advanced Micro Devices (NYSE:AMD), Corning (NYSE:GLW), and Apollo Group (NASDAQ:APOL).
- Research articles 2006-01-20
- Zacks Bull and Bear of the Day Highlights: Snap-on, MannKind Corp., NVIDIA and Public Storage
- CHICAGO -- Zacks Equity Research highlights Snap-on, Inc. (NYSE: SNA) as the Bull of the Day and MannKind Corp. (Nasdaq: MNKD) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on NVIDIA (Nasdaq: NVDA) and Public Storage (NYSE: PSA). Full analysis of all four stocks is...
- Research articles 2007-09-17
- Zacks Analyst Blog Highlights: EnCana, MannKind, Pfizer, Eli Lilly and Novo Nordisk
- CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: EnCana (NYSE: ECA), MannKind (Nasdaq: MNKD), Pfizer (NYSE: PFE), Eli Lilly...
- Research articles 2008-05-07
- Zacks Bull and Bear of the Day Highlights: Net Servicos, MannKind, WPP Group and Tessera
- CHICAGO -- Zacks Equity Research highlights Net Servi[?]os de Comunica[?]ao (Nasdaq: NETC) as the Bull of the Day and MannKind Corporation (Nasdaq: MNKD) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on WPP Group (Nasdaq: WPPGY) and Tessera Technologies (Nasdaq: TSRA). Full analysis of all...
- Research articles 2007-02-07
- Zacks Bull and Bear of the Day Highlights: Verisign, MannKind, Ford and Lamar Advertising
- CHICAGO -- Zacks Equity Research highlights Verisign, Inc. (Nasdaq: VRSN) as the Bull of the Day and MannKind Corp. (Nasdaq: MNKD) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Ford (NYSE: F) and Lamar Advertising Company (Nasdaq: LAMR). Full analysis of all these stocks...
- Research articles 2008-01-04
- Zacks Bull and Bear of the Day Highlights: Southern Copper, MannKind Corp., HouseValues and VNUS Medical Technologies
- CHICAGO -- Zacks Equity Research highlights Southern Copper Corp. (NYSE:PCU) as the Bull of the Day and MannKind Corp. (Nasdaq:MNKD) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on HouseValues (Nasdaq:SOLD) and VNUS Medical Technologies (Nasdaq:VNUS). Full analysis of all four stocks is available at...
- Research articles 2006-08-08
- Zacks Bull and Bear of the Day Highlights: Aracruz Celulose, MannKind Corp., Superior Industries and RenaissanceRe
- CHICAGO -- Zacks Equity Research highlights Aracruz Celulose S.A. (NYSE:ARA) as the Bull of the Day and MannKind Corp. (Nasdaq:MNKD) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Superior Industries (NYSE:SUP) and RenaissanceRe (NYSE:RNR). Full analysis of all four stocks is available at http://at.zacks.com/?id=2676.
- Research articles 2006-07-11
- ImVisioN GmbH Obtains an Exclusive License from Mannkind Corporation to Patents Covering the Intralymphatic Administration of Allergens
- HANOVER, Germany -- ImVisioN GmbH today announced that MannKind Corporation has granted to ImVisioN an exclusive world-wide license to the US Patent 6,773,695 B2 and its foreign counterparts. Financial terms of the transaction have not been disclosed.
- Research articles 2006-03-02
- << Previous
- page 1 of 1
- Next >>
